Loading
institutionsInstitution
European Association of Nuclear Medicine
Europe's nuclear medicine society, whose congress and guidelines shaped the clinical adoption of PSMA PET and lutetium radioligand therapy that began in European centres.
Also called: EANM
Overview
Founded in 1985 and based in Vienna, EANM represents nuclear medicine across Europe and publishes the European Journal of Nuclear Medicine and Molecular Imaging. Its annual congress is the largest nuclear medicine meeting in Europe and was the early forum for PSMA-PET and Lu-177 PSMA work from Heidelberg, Munich, Bad Berka and other centres before the VISION trial. EANM issues procedure guidelines with SNMMI on PSMA PET, PRRT for neuroendocrine tumours, dosimetry and FDG PET response criteria, runs the EARL accreditation programme that harmonises PET scanners across trial sites, and operates the European School of Multimodality Imaging and Therapy. It advocates on isotope supply and reimbursement for theranostics in Europe.
Location
Vienna, AT
Type
consortium
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#294 · 22 points (0 Newsweek + 0 NCI + 22 from 11 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to European Association of Nuclear Medicine, including child institutions. 6 works · 88 citations · 83% open access · 17% clinical trials · 0% reviews.
Oncology works per year
22022
42023
02024
02025
02026
Most works
- Smiths Lueong3 works
- Stephan A. Hahn3 works
- E. Smeets3 works
- Konstantinos Savvatakis3 works
- Rickmer Braren3 works
- Laura Godfrey3 works
- Corinna Münch3 works
- Jörg D. Hoheisel3 works
- Wilko Weichert3 works
- Irina Heid3 works
Most cited
| Work | Journal | Year | Citations |
|---|---|---|---|
| Emerging and Evolving Concepts in Cancer Immunotherapy Imaging 10.1148/radiol.210518 | Radiology | 2022 | 59 |
| Summary: Appropriate Use Criteria for Lymphoscintigraphy in Sentinel Node Mapping and Lymphedema/Lipedema 10.2967/jnumed.123.265560 · open access | Journal of Nuclear Medicine | 2023 | 20 |
| Use of information and communication technologies (ICTs) in cancer multidisciplinary team meetings: an explorative study based on EU healthcare professionals 10.1136/bmjopen-2021-051181 · open access | BMJ Open | 2022 | 9 |
| Additional file 3 of Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma | Figshare | 2023 | 0 |
| Additional file 5 of Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma | Figshare | 2023 | 0 |
| Additional file 4 of Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma | Figshare | 2023 | 0 |
- EANM Congress
- EARL PET accreditation
- Procedure guidelines (with SNMMI)
- European Journal of Nuclear Medicine and Molecular Imaging
- ESMIT education
Ken Herrmann
Chair of Nuclear Medicine, University Hospital Essen
TheranosticsPSMA radioligand therapyNuclear medicine
Nuclear medicine leader who co-led VISION and runs one of the world's largest theranostics programmes.
Paola Anna Erba
President (2025-2026)
Nuclear medicineTheranosticsMolecular imaging
Italian nuclear medicine physician serving as President of the European Association of Nuclear Medicine.
Uwe Haberkorn
Head of Nuclear Medicine, Heidelberg University Hospital and DKFZ
Nuclear medicineFAP-targeted radiopharmaceuticalsTheranostics
Nuclear medicine physician whose group invented FAPI PET tracers and pioneered PSMA and FAP radioligand therapy.
Frederik Giesel
Director of Nuclear Medicine, University Hospital Düsseldorf; formerly Heidelberg
Molecular imagingFAPI PETPSMA theranostics
Frederik Giesel co-developed FAPI PET imaging and now leads nuclear medicine in Düsseldorf.
Clemens Kratochwil
Nuclear medicine physician, Heidelberg University Hospital
Targeted alpha therapyPSMA radioligandsDosimetry
Clemens Kratochwil reported the first patients treated with actinium-225 PSMA therapy.
Similar pages
- IdeaA university cyclotron network with shared regulatory files for new tracers
Shares Frederik Giesel, Uwe Haberkorn, Heidelberg University Hospital / NCT / DKFZ, FAPI PET.
- InstitutionChulabhorn Hospital / Chulabhorn Royal Academy
Shares Theranostics, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Targeted alpha therapy.
- InstitutionTUM Klinikum rechts der Isar / CCC München
Shares LMU Klinikum München, Theranostics, FAPI PET, Lutetium-177 dotatate.
- InstitutionUniversity Hospital Düsseldorf / CIO Düsseldorf
Shares Frederik Giesel, Heidelberg University Hospital / NCT / DKFZ, FAPI PET, Lutetium-177 vipivotide tetraxetan.
- InstitutionInselspital, Bern University Hospital / University Cancer Center Inselspital
Shares Dosimetry, Theranostics, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan.
- Key paperVISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer
Shares Ken Herrmann, Dosimetry, Theranostics, Lutetium-177 vipivotide tetraxetan.
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Dosimetry, Theranostics, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan.
- InstitutionPostgraduate Institute of Medical Education and Research, Chandigarh
Shares FAPI PET, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, PSMA PET.
fronts
technologies
drugs
ApprovedRadioligand therapy (beta)
Lutetium-177 dotatate · Lutathera
ApprovedRadioligand therapy (beta)
Lutetium-177 vipivotide tetraxetan · Pluvicto